Catalent, Inc. (CTLT) |
|
56.515 1.795 (3.28%)
|
02-02 15:06 |
|
Open: |
55.54 |
Pre. Close: |
54.72 |
|
High:
|
57.955 |
Low:
|
55.43 |
|
Volume:
|
2,283,052 |
Market Cap:
|
10,171(M) |
|
|
|
Technical analysis |
as of: 2023-02-02 2:40:36 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 67.69 One year: 79.06 |
| Support: |
Support1: 48.66 Support2: 42.91 |
| Resistance: |
Resistance1: 57.95 Resistance2: 67.69 |
| Pivot: |
51.26 |
| Moving Average: |
MA(5): 54.22 MA(20): 50.43
MA(100): 57.69  MA(250): 84.75 |
| MACD: |
MACD(12,26): 2 Signal(9): 1.3 |
| Stochastic oscillator: |
%K(14,3): 92.2 %D(3): 89.2 |
| RSI: |
RSI(14): 70.2 |
| 52-week: |
High: 115.33 Low: 40.68 |
| Average Vol(K): |
3-Month: 2,940 (K) 10-Days: 2,194 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CTLT ] has closed above the upper band by 3.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 39.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
54.87 - 55.07 |
55.07 - 55.23 |
|
Low:
|
51.6 - 51.85 |
51.85 - 52.06 |
|
Close:
|
54.33 - 54.73 |
54.73 - 55.05 |
|
Company Description |
|
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey. |
Headline News |
Thu, 02 Feb 2023
Cal Poly’s CTLT begins winter quarter Book Circle - Mustang News
Thu, 02 Feb 2023
Validea Daily Guru Fundamental Report for CTLT - 2/2/2023 - Nasdaq
Wed, 01 Feb 2023
Is Catalent Inc (CTLT) Stock a Good Value? - InvestorsObserver
Tue, 31 Jan 2023
Catalent (CTLT) Expected to Beat Earnings Estimates: What to Know ... - Nasdaq
Mon, 30 Jan 2023
Vontobel Holding Ltd. Has $1.16 Million Stake in Catalent, Inc ... - MarketBeat
Wed, 25 Jan 2023
Validea Daily Guru Fundamental Report for CTLT - 1/25/2023 - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
180 (M) |
| Shares Float |
179 (M) |
|
% Held by Insiders
|
0.3 (%) |
|
% Held by Institutions
|
101.8 (%) |
|
Shares Short
|
5,980 (K) |
|
Shares Short P.Month
|
5,070 (K) |
Stock Financials |
|
EPS
|
2.48 |
|
EPS Est Next Qtl
|
0.36 |
|
EPS Est This Year
|
1.62 |
|
EPS Est Next Year
|
1.82 |
|
Book Value (p.s.)
|
26.11 |
|
Profit Margin (%)
|
8.8 |
|
Operating Margin (%)
|
14.8 |
|
Return on Assets (ttm)
|
4.3 |
|
Return on Equity (ttm)
|
9.3 |
|
Qtrly Rev. Growth
|
-0.4 |
|
Gross Profit (p.s.)
|
9.11 |
|
Sales Per Share
|
26.78 |
|
EBITDA (p.s.)
|
6.16 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
184 (M) |
|
Levered Free Cash Flow
|
-454 (M) |
Stock Valuations |
|
PE Ratio
|
22.83 |
|
PEG Ratio
|
1.9 |
|
Price to Book value
|
2.16 |
|
Price to Sales
|
2.11 |
|
Price to Cash Flow
|
55.39 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
